top of page



-0.03 (-0.40%)

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low


52 wk hi




Burn Rate (Qtr)


Mkt Cap


Avg Volume


*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name




Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by



Company Profile

BELLUS Health (Nasdaq:BLU, TSX:BLU) is a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of chronic cough and other hypersensitization-related disorders. The Company’s product candidate, BLU-5937, is being developed for the treatment of chronic cough and chronic pruritus. BLU-5937 is a highly selective P2X3 antagonist that has the potential to be a differentiated treatment option for patients that suffer from either condition. The Company is exploring how P2X3 activation contributes to irritation and pain, and whether inhibition of P2X3 receptors can help treat other afferent hypersensitization-related disorders.

Recent Posts

See what the community is saying - click to see full post.

bottom of page